ABILIFY® (aripiprazole) Savings Program
Terms and Conditions

Retail pharmacy option:

With this Savings Card, eligible, commercially insured patients can save on their out-of-pocket costs and pay as little as $5 per co-pay for their ABILIFY prescriptions. When the co-pay for a 30-day supply is above $5, all eligible, commercially insured patients will pay the first $5, total benefit not to exceed the list price, as determined by Otsuka America Pharmaceutical, Inc. (OAPI) and communicated to your pharmacy. Any day dispenses are permissible within the terms of the program. This card must be activated by calling 1-888-922-4543. You can continue to use this card for as long as you are eligible or until this program is terminated. (Limit 1 card per patient.) The card is not transferable. Patients are not eligible if they pay cash for their prescriptions; or are covered in whole or in part by any state or federally funded programs, including, but not limited to, Medicare or Medicaid (including Medicaid managed care), Medigap, VA, DOD, or TRICARE. Only valid in U.S. and Puerto Rico, but not for residents of Massachusetts, California or where otherwise prohibited by law. Offer void where prohibited by law, taxed, or restricted. Other conditions may apply.

To receive the benefits of this program, you must present the Savings Card to your pharmacist along with a valid ABILIFY prescription. This program is not health insurance. OAPI has the right to rescind, revoke, or amend this program without notice. Your participation in this program confirms that this offer is consistent with your insurance coverage and that you will report the value received if required by your insurance provider. When you use this card, you are certifying that you understand and will comply with the program rules, terms, and conditions. For questions, please call 1-888-9-ABILIFY (1-888-922-4543) 8 AM–7 PM ET, Monday–Friday. Notice to the pharmacy: When you use this card, you are certifying that you have not submitted and will not submit a claim for reimbursement under any federal, state, or other governmental programs for this prescription. As a condition of payment, you certify that you are in compliance with all program rules, terms, and conditions, as well as with any obligations to provide notice of your participation in this program to third-party payers as required by law, contract, or otherwise.

  • Submit transaction using Bin #015251. Processor requires Valid Prescriber ID#, Patient Name, and DOB for claim adjudication
  • If primary coverage exists, input card information as secondary coverage and transmit using the COB fields with other coverage code type 08 of the NCPDP transaction. Applicable discounts will be displayed in the transaction response

Mobile terms:

By agreeing to the terms of ABILIFY Mobile Program (Program), you consent to receive autodialed text messages on behalf of Otsuka America Pharmaceutical, Inc. (OAPI). Consent is not a condition of purchase or use of any OAPI product. The Program is valid with most major US carriers. There is no fee payable to OAPI to receive text messages; however, your carrier’s message and data rates may apply.

Data obtained from you in connection with your registration for, and use of, this service may include your phone number, related carrier information, and elements of pharmacy claim information. This data will only be used to administer this program and to provide program benefits such as savings offers, information about your prescription, refill reminders, as well as program updates and alerts sent directly to your device.

Participants may receive an average of 5 messages per month during the course of this program. You may unsubscribe from the Program at any time by texting STOP. For help, text HELP or contact your mobile carrier. For questions about the program or the card call 1-888-922-4543. OAPI reserves the right to rescind, revoke or amend the Program without notice.

Home delivery option:

With the ABILIFY savings program home delivery option, eligible, commercially insured patients can save on their out of pocket costs and pay as little as $0 per co-pay for their ABILIFY prescriptions. When the co-pay is above $0, all eligible, commercially insured patients will pay $0, total benefit not to exceed the list price, as determined by Otsuka America Pharmaceutical, Inc. (OAPI) and communicated to Cardinal Health Specialty Pharmacy. You can continue to use this program for as long as you are eligible or until this program is terminated. (Limit 1 offer per patient.) The offer is not transferable. Patients are not eligible if they pay cash for their prescriptions; or are covered in whole or in part by any state or federally funded programs, including, but not limited to, Medicare or Medicaid (including Medicaid managed care), Medigap, VA, DOD, or TRICARE. Only valid in U.S. and Puerto Rico, but not for residents of Massachusetts, California or where otherwise prohibited by law. Offer void where prohibited by law, taxed, or restricted. Other conditions may apply.

This program is not health insurance. OAPI has the right to rescind, revoke, or amend this program without notice. Your participation in this program confirms that this offer is consistent with your insurance coverage and that you will report the value received if required by your insurance provider. When you enroll in this program, you are certifying that you understand and will comply with the program rules, terms, and conditions. For questions, please call 1-888-9-ABILIFY (1-888-922-4543) 8 AM–7 PM ET, Monday–Friday.

IMPORTANT SAFETY INFORMATION and INDICATIONS for ABILIFY® (aripiprazole)

 

IMPORTANT SAFETY INFORMATION:

Elderly people with psychosis related to dementia (for example, an inability to perform daily activities as a result of increased memory loss), treated with antipsychotic medicines including ABILIFY, are at an increased risk of death compared to placebo. ABILIFY is not approved for the treatment of people with dementia-related psychosis (see BOXED WARNING).

Antidepressant medicines may increase suicidal thoughts or behaviors in some children, teenagers, and young adults, especially within the first few months of treatment or when the dose is changed. Depression and other serious mental illnesses are themselves associated with an increase in the risk of suicide. Patients on antidepressants and their families or caregivers should watch for new or worsening depression symptoms, unusual changes in behavior, or thoughts of suicide. Such symptoms should be reported to the patient's healthcare provider right away, especially if they are severe or occur suddenly. ABILIFY is not approved for use in pediatric patients with depression (see BOXED WARNING).

Contraindication: Do not take ABILIFY if you are allergic to aripiprazole or any of the ingredients in ABILIFY. Allergic reactions have ranged from rash, hives, and itching to anaphylaxis, which may include difficulty breathing, tightness in the chest, and swelling of the mouth, face, lips, or tongue.

ABILIFY may cause serious side effects, including:

  • Stroke in elderly people (cerebrovascular problems) that can lead to death
  • Neuroleptic malignant syndrome (NMS). Tell your healthcare provider right away if you have some or all of the following symptoms: high fever, stiff muscles, confusion, sweating, changes in pulse, heart rate, and blood pressure. These may be symptoms of a rare and serious condition that can lead to death. Call your healthcare provider right away if you have any of these symptoms.
  • Uncontrolled body movements (tardive dyskinesia). ABILIFY may cause movements that you cannot control in your face, tongue, or other body parts. Tardive dyskinesia may not go away, even if you stop receiving ABILIFY. Tardive dyskinesia may also start after you stop receiving ABILIFY.
  • Problems with your metabolism such as:
    • High blood sugar (hyperglycemia) and diabetes. Increases in blood sugar can happen in some people who take ABILIFY. Extremely high blood sugar can lead to coma or death. If you have diabetes or risk factors for diabetes (such as being overweight or a family history of diabetes), your healthcare provider should check your blood sugar before you start ABILIFY and during your treatment.

      Call your healthcare provider if you have any of these symptoms of high blood sugar while receiving ABILIFY:
      • feel very thirsty
      • need to urinate more than usual
      • feel very hungry
      • feel weak or tired
      • feel sick to your stomach
      • feel confused, or your breath smells fruity.
    • Increased fat levels (cholesterol and triglycerides) in your blood.
    • Weight gain. You and your healthcare provider should check your weight regularly.
  • Unusual urges. Some people taking ABILIFY have had unusual urges, such as gambling, binge eating or eating that you cannot control (compulsive), compulsive shopping and sexual urges.

    If you or your family members notice that you are having unusual urges or behaviors, talk to your healthcare provider.

  • Orthostatic hypotension (decreased blood pressure). Lightheadedness or fainting may happen when rising too quickly from a sitting or lying position.
  • Low white blood cell count
  • Seizures (convulsions)
  • Problems with control of your body temperature especially when you exercise a lot or are in an area that is very hot. It is important for you to drink water to avoid dehydration. Avoid getting over-heated or dehydrated. Do not over-exercise. In hot weather, stay inside in a cool place if possible. Stay out of the sun. Do not wear too much or heavy clothing. Drink plenty of water.
  • Difficulty swallowing that can cause food or liquid to get into your lungs.

Do not drive, operate heavy machinery, or do other dangerous activities until you know how ABILIFY affects you. ABILIFY may make you drowsy.

While taking ABILIFY, avoid drinking alcohol.

Before taking ABILIFY, tell your healthcare provider about all your medical conditions, including if you have or had:

  • diabetes or high blood sugar in you or your family; your healthcare provider should check your blood sugar before you start ABILIFY and also during therapy.
  • seizures (convulsions).
  • low or high blood pressure.
  • heart problems or stroke.
  • pregnancy or plans to become pregnant. It is not known if ABILIFY will harm your unborn baby.
  • breast-feeding or plans to breast-feed. ABILIFY can pass into your breast milk and may harm your baby. Talk to your healthcare provider about the best way to feed your baby if you receive ABILIFY.
  • low white blood cell count.
  • phenylketonuria. ABILIFY DISCMELT® Orally Disintegrating Tablets contain phenylalanine.

For patients who must limit their sugar intake, ABILIFY Oral Solution contains sugar.

Tell your healthcare provider about all the medicines that you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.

ABILIFY and other medicines may affect each other causing possible serious side effects. ABILIFY may affect the way other medicines work, and other medicines may affect how ABILIFY works. Do not start or stop any medicines while taking ABILIFY without talking to your healthcare provider first.

The most common side effects of ABILIFY in adults include: nausea, vomiting, constipation, headache, blurred vision, upper respiratory illness, dizziness, anxiety, insomnia, restlessness, and inner sense of restlessness or need to move (akathisia).

The most common side effects of ABILIFY in children include: feeling sleepy, headache, vomiting, fatigue, increased or decreased appetite, increased saliva or drooling, insomnia, nausea, stuffy nose, weight gain, uncontrolled movement such as restlessness or tremor, and muscle stiffness.

It is important to contact your healthcare provider if you experience prolonged, abnormal muscle spasms or contractions, which may be signs of a condition called dystonia.

These are not all the possible side effects of ABILIFY.

Call your doctor for medical advice about side effects.

If you have any questions about your health or medicines, talk to your healthcare provider.

You are encouraged to report side effects of ABILIFY. Please contact Otsuka America Pharmaceutical, Inc. at 1-800-438-9927 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

INDICATIONS: ABILIFY is indicated for:

  • Treatment of Schizophrenia in adults and in adolescents 13 to 17 years of age
  • Treatment of manic or mixed episodes associated with Bipolar I Disorder in adults and in pediatric patients 10 to 17 years of age
  • Use as an add-on treatment to an antidepressant for adults with Major Depressive Disorder who have had an inadequate response to antidepressant therapy
  • Treatment of irritability associated with Autistic Disorder in pediatric patients 6 to 17 years of age
  • Treatment of Tourette's Disorder in pediatric patients 6 to 18 years of age

Special Considerations for Pediatric Uses:

  • Discuss the risks and benefits of treatment with your child's healthcare provider. Treatment should be started only after a thorough diagnostic evaluation and as part of a total treatment program

Please see FULL PRESCRIBING INFORMATION, including BOXED WARNING, and MEDICATION GUIDE